Search results for "Respiratory system"

showing 10 items of 1829 documents

Supplementary Material for: Validation of Fenoterol to Study ��2-Adrenoceptor Function in the Rat Urinary Bladder

2021

Fenoterol is a ��2-adrenoceptor (AR)-selective agonist that is commonly used to investigate relaxation responses mediated by ��2-AR in smooth muscle preparations. Some data have questioned this because fenoterol had low potency in the rat urinary bladder when a muscarinic agonist was used as a pre-contraction agent and because some investigators proposed that fenoterol may act in part via ��3-AR. We designed the present study to investigate whether fenoterol is a proper pharmacological tool to study ��2-AR-mediated relaxation responses in the rat urinary bladder. Firstly, we have compared the effect of pre-contraction agents on fenoterol potency and found that fenoterol potency was about 1.…

respiratory system
researchProduct

Elucidating the aryl hydrocarbon receptor antagonism from a chemical-structural perspective

2020

The aryl hydrocarbon receptor (AhR) plays an important role in several biological processes such as reproduction, immunity and homoeostasis. However, little is known on the chemical-structural and physicochemical features that influence the activity of AhR antagonistic modulators. In the present report, in vitro AhR antagonistic activity evaluations, based on a chemical-activated luciferase gene expression (AhR-CALUX) bioassay, and an extensive literature review were performed with the aim of constructing a structurally diverse database of contaminants and potentially toxic chemicals. Subsequently, QSAR models based on Linear Discriminant Analysis and Logistic Regression, as well as two tox…

respiratory system
researchProduct

Early childhood growth is associated with lung function at 7 years: a prospective population-based study

2020

Previous studies have related early postnatal growth with later lung function but their interpretation is limited by the methods used to assess a child's growth. We aimed to assess the association of early childhood growth, measured by body mass index (BMI) trajectories up to 4 years, with lung function at 7 years.We included 1257 children from the Spanish Infancia y Medio Ambiente population-based birth cohort. Early childhood growth was classified into five categories based on BMI trajectories up to 4 years previously identified using latent class growth analysis. These trajectories differed in birth size ("lower", "average", "higher") and in BMI gain velocity ("slower", "accelerated"). W…

respiratory systemrespiratory tract diseases
researchProduct

Additional file 1: of MUC1 deficiency mediates corticosteroid resistance in chronic obstructive pulmonary disease

2018

Figure S1. Acute cigarette smoke/ lipopolysaccharide lung inflammatory animal model showed resistance to dexamethasone improving lung resistance and bronchoalveolar inflammatory cell extravasation in Muc1 KO animals. Figure S2. IL-8 and IL-13 bronchoalveolar fluid content in Muc1 KO mice exposed to acute cigarette smoke/ lipopolysaccharide is resistant to dexamethasone. Figure S3. Inflammatory lung cell infiltration secondary to acute lipopolysaccharide/ cigarette smoke exposure is resistant to dexamethasone in MUC1 KO mice. (DOCX 1611 kb)

respiratory systemrespiratory tract diseases
researchProduct

Lung Deposition Using the Respimat® Soft Mist™ Inhaler Mono and Fixed-Dose Combination Therapies: An In Vitro/In Silico Analysis

2021

Tiotropium and olodaterol are mainstay treatments for chronic obstructive pulmonary disease (COPD) and yield important clinical improvements, especially when used in fixed-dose combination. Whilst previous studies have shown consistent delivery of tiotropium to the lungs with the Respimat® inhaler, no such study has been carried out for olodaterol or the components of their fixed-dose combination (TIO/OLO). Combining in vitro and in silico models, we measured the amount of drug retained in the mouth–throat area, entering the trachea and reaching the lung periphery. We applied a hybrid deposition model that considered the experimentally determined output of an Alberta throat model (in vitro …

respiratory systemrespiratory tract diseases
researchProduct

Mucin 1 deficiency mediates corticosteroid insensitivity in asthma

2019

BACKGROUND: The loss of corticosteroid efficacy is an important issue in severe asthma management and may lead to poor asthma control and deterioration of airflow. Recent data indicate that Mucin 1 (MUC1) membrane mucin can mediate corticosteroid efficacy in chronic rhinosinusitis, but the role of MUC1 in uncontrolled severe asthma is unknown. The objective was to analyze the previously unexplored role of MUC1 on corticosteroid efficacy in asthma. METHODS: Mucin 1 expression was evaluated by real-time PCR in human bronchial epithelial cells (HBEC) and blood neutrophils from uncontrolled severe asthma (n=27), controlled mild asthma (n=16), and healthy subjects (n=13). IL-8, MMP9, and GM-CSF …

severe asthma0301 basic medicineLipopolysaccharideNeutrophilsmedicine.drug_classcorticosteroid insensitivityImmunologyAnti-Inflammatory AgentsDrug ResistanceMUC1DexamethasoneMice03 medical and health scienceschemistry.chemical_compoundReceptors Glucocorticoid0302 clinical medicineGlucocorticoid receptorAdrenal Cortex Hormonesimmune system diseasesmedicineAnimalsHumansImmunology and AllergyCells CulturedMUC1DexamethasoneAsthmabiologybusiness.industryMucin-1MucinEpithelial Cellsmedicine.diseaseAsthmarespiratory tract diseasesOvalbumin030104 developmental biology030228 respiratory systemchemistryCase-Control StudiesImmunologybiology.proteinCorticosteroidbusinessmedicine.drugAllergy
researchProduct

Real-world experience with dupilumab in severe asthma: One-year data from an italian named patient program

2021

Raffaele Campisi,1 Claudia Crimi,1 Santi Nolasco,2 Bianca Beghè,3 Leonardo Antonicelli,4 Gabriella Guarnieri,5 Nicola Scichilone,6 Morena Porto,2 Luigi Macchia,7 Giulia Scioscia,8 Maria Pia Foschino Barbaro,8 Alberto Papi,9 Nunzio Crimi1,2 1Respiratory Medicine Unit, A.O.U. Policlinico “G. Rodolico -San Marco”, Catania, Italy; 2Department of Clinical and Experimental Medicine, Section of Respiratory Diseases, University of Catania, Catania, Italy; 3Respiratory Medicine Unit, Department of Medicine, University of Modena and Reggio Emilia, Modena, Italy; 4Allergy Unit, Department of Internal Medicine, Ancona University Hospital, Ancona, Italy; 5Department of Car…

severe asthmaPulmonary and Respiratory MedicineSevere asthmareal-worldmedicine.medical_specialtyTreatment responseSevere asthmaSocio-culturaleDupilumab Named Patient Program Oral corticosteroids Real-world Severe asthmaHypereosinophiliaDupilumaboral corticosteroidsSettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.inventionNamed Patient Program dupilumab oral corticosteroids real-world severe asthma03 medical and health sciences0302 clinical medicineRandomized controlled triallawdupilumabInternal medicineOral corticosteroidsJournal of Asthma and AllergymedicineImmunology and Allergy0601 history and archaeologyOriginal Research060102 archaeologybusiness.industryRetrospective cohort study06 humanities and the artsRC581-607Named Patient ProgramEosinophilDupilumabmedicine.anatomical_structureReal-world030228 respiratory systemCohortImmunologic diseases. Allergymedicine.symptombusinessDupilumab; Named Patient Program; Oral corticosteroids; Real-world; Severe asthma
researchProduct

Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma

2021

BACKGROUND: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date. METHODS: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow-up. The primary outcome was the evolution of…

severe asthmamedicine.medical_specialtyPediatricsImmunology*real lifeOmalizumabhumanized monoclonal antibodiesOmalizumab*adolescentsAntibodies Monoclonal HumanizedAnti-asthmatic Agent03 medical and health sciences0302 clinical medicinechildrenreal lifeInternal medicinemedicine*anti-asthmatic agents*childrenHumansImmunology and AllergyChildren adolescents anti-asthmatic agents humanized monoclonal antibodies observational study omalizumab real-life severe asthmaAnti-Asthmatic Agentsadolescents030212 general & internal medicineChildAdverse effectRetrospective Studiesbusiness.industryasthmatic agents*observational studyanti&#8208Retrospective cohort studyAsthmaDiscontinuation*omalizumabTreatment OutcomePulmonology030228 respiratory system*humanized monoclonal antibodies*severe asthmaSevere persistent allergic asthmaPediatrics Perinatology and Child HealthCohortomalizumabobservational studyObservational studybusinessmedicine.drugPediatric Allergy and Immunology
researchProduct

The hidden burden of severe asthma: from patient perspective to new opportunities for clinicians

2020

Severe asthma is an important topic in respiratory diseases, due to its high impact on morbidity and mortality as well as on health-care resources. The many challenges that still exist in the management of the most difficult-to-treat forms of the disease, and the acknowledgement of the existence of unexplored areas in the pathophysiological mechanisms and the therapeutic targets represent an opportunity to gather experts in the field with the immediate goals to summarize current understanding about the natural history of severe asthma and to identify gaps in knowledge and research opportunities, with the aim to contribute to improved medical care and health outcomes. This article is a conse…

severe asthmamedicine.medical_specialtySevere asthmaprecision medicineAcknowledgementlcsh:MedicineSocio-culturaleReviewDiseasebiomarkers patient’s perspective precision medicine severe asthma.Medical care03 medical and health sciencesTherapeutic approach0302 clinical medicineMedicine030212 general & internal medicineddc:610Intensive care medicinebusiness.industrylcsh:RPerspective (graphical)General MedicineResearch opportunitiesBiomarkers patient’s perspective precision medicine severe asthmaBiomarkers; Patient’s perspective; Precision medicine; Severe asthmapatient’s perspectiveNatural history030228 respiratory systembusinessBiomarkers
researchProduct

Sleep Disturbances in COPD are Associated with Heterogeneity of Airway Obstruction

2018

Individuals with Chronic Obstructive Pulmonary Disease (COPD) experience sleep disturbances due to the impact of respiratory symptoms on sleep quality. We explored whether sleep disturbances in COPD are linked to heterogeneity of airway constriction.The impact of breathing problems on sleep quality was measured in consecutive COPD outpatients with the COPD and Asthma Sleep Impact Scale (CASIS) questionnaire. Impulse oscillometry technique (IOS) was employed to assess heterogeneity of airway constriction. Subjects with a previous or concomitant diagnosis of asthma or obstructive sleep apnea (OSA) were excluded.Fifty COPD subjects (M/F 40/10; age: 71 +/- 8 yrs, Body Mass Index (BMI): 26.2 +/-…

sleep abnormalitieMaleSleep Wake DisordersPulmonary and Respiratory Medicinemedicine.medical_specialtyPulmonary diseaseCASISSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineForced Expiratory VolumeOscillometrySurveys and QuestionnairesInternal medicinemedicineCOPDHumansSleep Wake DisorderOximetry030212 general & internal medicineRespiratory systemOxyhemoglobinAgedIOSCOPDSleep qualitybusiness.industryMiddle AgedAirway obstructionmedicine.diseaseSleep in non-human animalsSleep abnormalitiesResidual Volume030228 respiratory systemOxyhemoglobinsCardiologyFemalebusinessHumanCOPD: Journal of Chronic Obstructive Pulmonary Disease
researchProduct